Business Description

Agenus Inc. is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer and infectious diseases. Headquartered in Massachusetts, the company focuses on activating the body's immune system through a portfolio of checkpoint inhibitors, immune modulators, and cell therapies. Agenus is notable for its proprietary Retrocyte Display antibody expression platform and its development of the QS-21 Stimulon vaccine adjuvant.

Everything on Agenus Inc.

Revenue (FY2025) $114M
YoY growth +10.4%
Operating margin -17.7%
Direction Expanding
Gross margin 99.1%
Net margin -0.1%

Earnings Transcripts

View all transcripts ↗

Leadership & board

View leadership ↗

Customer Concentration

Agenus's revenue is highly concentrated in a single collaboration partner: 95%, 98% and 73% of revenue was earned from one collaboration partner for the years ended December 31, 2025, 2024 and 2023, respectively.

Recent SEC Filings

2026-08-11 Leadership change (directors/officers) View filing ↗
2026-08-06 Reported quarterly results View filing ↗
2026-07-13 Entered a material agreement (+3 more) View filing ↗
2026-07-06 Entered a material agreement View filing ↗
2026-06-23 Shareholder vote results View filing ↗
2026-05-15 Leadership change (directors/officers) View filing ↗
2026-05-11 Reported quarterly results View filing ↗
2026-03-26 Other event View filing ↗
2026-03-16 Reported quarterly results View filing ↗
2026-01-16 Completed an acquisition or disposition (+2 more) View filing ↗
2026-01-14 Leadership change (directors/officers) View filing ↗
2026-01-08 Entered a material agreement (+1 more) View filing ↗

More Companies

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.